

Greg Fenton on Zentek's approval for Nasdaq listing and the expanding use of its highly effective anti-microbial ZenGUARD™ coating

written by InvestorNews | March 15, 2022

In a recent InvestorIntel interview, Tracy Weslosky spoke with Greg Fenton, CEO and Director of [Zentek Ltd.](#) (TSXV: ZEN) about Zentek's recent [news release](#) on receiving approval to list on the Nasdaq and about [engaging Vimta Labs](#) to begin studies of ZenGUARD™ active ingredient as a potential treatment of infectious skin disease.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Greg Fenton provided an update on Zentek's "unique and innovative" ZenGUARD™ antimicrobial coating which is "proven to be more than 99% effective in reducing the physical spread of the SARS-CoV-2" and other pathogens. He went on to say that Zentek will be publishing the patent application for the ZenGUARD™ antimicrobial coating on March 21, 2022.

To watch the full interview, [click here](#).

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to

have 99% effectiveness in antimicrobial activity reduction, including against the COVID-19 pathogens, and the potential to use similar compounds as products against other infectious diseases. The Company also has an exclusive agreement to be the global commercializing partner for a newly developed rapid aptamer-based pathogen detection technology.

To learn more about Zentek Ltd., [click here](#).

Disclaimer: *Zentek Ltd. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or

results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.